BIO-TECHNE Corp

TECH · Health care (biological products, (no diagnostic substances)) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2026-06-30

Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›

BIO-TECHNE Corp reported revenue of $1.2 billion in fiscal 2026, after growing 8.9% a year over the previous 9 years. Its operating margin held steady at about 20.7% from 2017. Of the $2.5 billion its operations generated over 10 years, 44.1% went to acquisitions and 27.3% to buybacks; the share count rose 4.7%. On the accounting screens, it passes 7 of 8 Piotroski tests, its Altman Z'' of 8.20 is in the safe zone and its Beneish M-score is below the -1.78 line; 1 of the six cross-checks between its statements fires.

Revenue, fiscal 2026 1.2B +8.9% a year over 9 years

Operating margin 20.7% gross margin 65.8%

Return on invested capital — 15.1% on average over 1 years

Free cash flow after stock pay 221.9M 18.3% of revenue

Net debt ÷ EBITDA — net debt —

Piotroski F-score 7/8 tests of improvement passed

Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units: 4-for-1 before fiscal 2021.

Is it growing?

Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.

RevenueOperating income

Compound growth a year
	3 yrs	5 yrs	9 yrs
Revenue	+2.2%	+5.5%	+8.9%
Operating income	-5.5%	+1.2%	+8.5%
Net income	-13.9%	+5.3%	+10.2%
Earnings per share	-13.1%	+6.0%	+9.6%
Free cash flow per share	+7.9%	-2.5%	+7.7%
Dividend per share	+0.8%	+0.7%	+0.1%
Shares	-1.0%	-0.6%	+0.5%

Falling shares are buybacks: each remaining share owns more of the company.

Does it earn more than its capital costs?

Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.

    GrossOperatingNetFree cash flow
    
  

Return on invested capital

Return on invested capital Cost of capital today · 10.2%

Economic profit

(return on capital − cost of capital) × capital invested: the profit left after paying for the money used. Today's cost of capital is applied to every year, since a past one cannot be rebuilt honestly.

Return on equity: 8.6%
Return on assets: 7.0%
Asset turnover: 0.47×
Research & development: 7.8% of revenue
Overheads (SG&A): 37.2% of revenue

Is the profit cash, and where does the cash go?

Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.

Net incomeFree cash flowAfter stock-based pay

Where 10 years of operating cash went, 2017–2026

2.5B generated by the business. Each band is its share of that total.

Reinvested in the business 14% 363.5M
Acquisitions 44% 1.1B
Dividends 20% 493.4M
Share buybacks 27% 686.7M
More than it generated: funded with cash or new debt -6% -139.5M

Over the same years it paid 358.2M in stock. The share count rose 4.7%. 328.5M of the buybacks went beyond offsetting that dilution.

Per share

    Earnings per shareFree cash flow per shareDividend per share
    
  

Shares outstanding

Diluted shares

How strong is the balance sheet?

Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.

Net debt

Net debt ÷ EBITDA: —
Interest coverage: 26× operating income ÷ interest
Current ratio: 4.55 current assets ÷ current liabilities
Cash conversion cycle: 213 days collects in 65d, stock 172d, pays in 23d

Three classic screens of the accounts

Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.

Piotroski F-score

Is the business improving? Nine yes-or-no tests, this year against last.

7of 8 tests passed

ProfitableReturn on assets above zero passed
Cash from operationsOperating cash flow above zero passed
Profitability improvedReturn on assets higher than a year before passed
Profit backed by cashOperating cash flow above net income (low accruals) passed
Less long-term debtLong-term debt as a share of assets fell — not reported no data
More liquidCurrent ratio higher than a year before passed
No new sharesShare count did not grow passed
Better gross marginGross margin higher than a year before passed
Sells more per assetAsset turnover higher than a year before failed

Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.

Altman Z''-score

Does the balance sheet look like those of companies that went bankrupt?

8.20safe zone

Working capital ÷ assets 0.22 × 6.56+1.47
Retained earnings ÷ assets 0.44 × 3.26+1.44
Operating income ÷ assets 0.10 × 6.72+0.65
Equity ÷ liabilities 4.41 × 1.05+4.63

Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.

Beneish M-score

Do the accounts resemble those of companies that manipulated their earnings?

-2.60below the -1.78 line

Receivables vs sales 1.05+0.97
Gross margin slipping 0.99+0.52
Soft assets 0.93+0.38
Sales growth 1.00+0.89
Slower depreciation 1.04+0.12
Overheads vs sales 0.77-0.13
Profit not in cash -0.04-0.20
Leverage rising 0.92-0.30

Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.

Where the statements disagree

Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.

Capital spending (29M) is well below depreciation (97M).

Benign

Mature assets, or a business that has become less capital-intensive.

Worrying

Under-investing: today's profit is being held up by consuming tomorrow's capacity.

What is it worth, under which assumptions?

A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.

Revenue

Starting revenue

M $

revenue of fiscal 2026

Growth in year one

revenue grew +5.5% a year over the last 5 years; it fades to the terminal rate by the last year

Years until it settles

yrs

ten years for growth to fade to the terminal rate

Cash from each sale

Free cash flow margin today

free cash flow to the firm after stock-based pay ÷ revenue, last 3 fiscal years together

Margin in the last year

the margin in year ten; by default the business keeps today's

Count stock-based pay as a costIt is paid in shares instead of cash, and shareholders bear it through dilution. Most free cash flow figures leave it out.

The long run

Growth after that, forever

growth forever after year ten, below the risk-free rate: no company outgrows the economy forever

The discount rate

Risk-free rate

10-year US Treasury par yield (U.S. Treasury), 2026-09-25

Beta

not measured on this public page, which uses only public filings: 1.0 assumes it moves like the market. Sign in to measure it from prices

Equity risk premium

the extra return demanded for holding shares; it cannot be measured, and 4–6% is the common range

Cost of debt, before tax

no interest line: the risk-free rate + 1.5 points

Tax rate

effective rate in the last fiscal year, 24.4%, kept within 0–35%

The price

Share price

Type the price you see at your broker. It is used only for the reverse questions: what that price implies.

Back to the defaults

SEC from the filings Treasury the 10-year yield measured from prices assumption cannot be measured yours you changed it

Value per share, with these assumptions $16.52 discounted at 10.2% a year · 50% of it from after year 10

$12.6780% of 5,000 simulations$22.19

Cautious $10.69 1.5% growth · 12.0% margin · 11.2% discount · 2.0% forever

Your assumptions $16.52 5.5% growth · 14.1% margin · 10.2% discount · 2.5% forever

Generous $26.79 9.5% growth · 16.3% margin · 9.2% discount · 3.0% forever

Type a share price on the left to ask the reverse questions: what growth, what margin or what discount rate that price implies.

What the value implies, in the usual multiples

	At this model's value
Price ÷ earnings	14.3×
Enterprise value ÷ EBITDA	7.4×
Enterprise value ÷ revenue	2.1×
Free cash flow yield	8.6%

From cash flows to a value per share

10 years of cash flow, today1.3B

Everything after, today1.3B

The whole business2.6B

Minus net debt-0

What belongs to shareholders2.6B

Divided among 157.0M shares: $16.52 each.

The projection next to its history

Reported free cash flow after stock pay, then the model's. A projection that looks nothing like the past needs a reason.

ReportedProjected

Year by year

	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036
Revenue	1.3B	1.3B	1.4B	1.5B	1.5B	1.6B	1.7B	1.7B	1.8B	1.8B
Growth	5.5%	5.2%	4.8%	4.5%	4.2%	3.8%	3.5%	3.2%	2.8%	2.5%
Cash margin	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%
Free cash flow	181.4M	190.7M	200.0M	209.0M	217.7M	226.0M	233.9M	241.3M	248.2M	254.4M
Worth today	164.6M	157.1M	149.5M	141.8M	134.1M	126.4M	118.7M	111.2M	103.8M	96.6M

If the least-known inputs move

Value per share as two inputs change at a time. Neighbouring cells that differ a lot are the conclusion: the value depends on numbers nobody knows to a point.

The discount rate and growth forever

discount ↓ · forever →	1.5%	2.0%	2.5%	3.0%	3.5%
9.2%	17	18	19	20	22
9.7%	16	17	18	19	20
10.2%	15	16	17	17	18
10.7%	14	15	15	16	17
11.2%	13	14	15	15	16

Year-one growth and the final margin

margin ↓ · growth →	1.5%	3.5%	5.5%	7.5%	9.5%
11.3%	12	13	14	15	16
12.7%	13	14	15	17	18
14.1%	14	15	17	18	19
15.6%	15	16	18	19	21
17.0%	16	18	19	21	22

All the inputs moving at once

5,000 valuations, each with growth, final margin, discount rate and growth forever drawn at random around the values on the left (spreads of 3.0%, 2.1%, 1.0% and 0.5%). Not a probability — the spreads are assumptions too — but an honest picture of how wide the answer is.

10th percentile$12.67

Median$16.57

90th percentile$22.19

Half of the simulations land between $14.33 and $19.12; one in ten below $12.67, one in ten above $22.19.

Does the long run make sense?

6.6×The terminal value prices the business in year 10 at 6.6 times that year's EBITDA.
26%To grow 2.5% forever while reinvesting 10% of its after-tax operating profit, the business must earn 26% on the new capital — it has earned 15% on average over the last five years.
50%of the value comes from after year 10. The more of it, the more the answer depends on the part nobody can see.

The discount rate, taken apart

What shareholders demand (CAPM): 5.17% risk-free + 1.00 beta × 5.0% premium = 10.17%.
What lenders charge, after the tax saving on interest: 6.67% × (1 − 24.4%) = 5.04%.
Weighted by how much of each the company uses (book value (no price given)): 10.17%, the rate every future cash flow is discounted at.

What it has filed lately

The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.

Event 2026-09-23

Published the results of a shareholder vote; published information for investors

Event 2026-09-14

Published other information

Annual 2026-08-24

Annual report

Results 2026-08-12

Reported results; published other information

Event 2026-06-26

Signed a material agreement; changed a director or officer

Event 2026-06-25

Published information for investors

Results 2026-05-06

Reported results; published other information

Quarterly 2026-05-06

Quarterly report

Estimatein 37d

Results for the period ending 2026-09-29

What its own directors and officers did

Every Form 4 filed in the last twelve months, read line by line: 6 filings by 6 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.

Bought on the open market—none in the period

Sold on the open market—none in the period

Under pre-arranged plans—of the sales followed a 10b5-1 plan set months earlier

Other lines20 awards · 1 option exercises · 1 tax withholdings

Date	Who	What	Shares	Price	Value	Holds after
22 Sep 2026	Baumgartner Robert VDirector	Exercised options	15,940	—	—	62,443
22 Sep 2026	Baumgartner Robert VDirector	Shares withheld for taxes	5,559	$72.55	$403,305	56,884

A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.

Which large funds report holding it

From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.

Fund	Shares	Value	Share of the fund	Since the quarter before
Ruane, Cunniff & Goldfarb 30 Jun 2026	3.3M	$236.6M	3.7%	Reduced
Maverick Capital 30 Jun 2026	1.5M	$108.5M	1.0%	Reduced
Norges Bank (Norway's sovereign fund) 30 Jun 2026	1.4M	$99.9M	0.0%	New
Tudor Investment 30 Jun 2026	943,287	$66.6M	0.3%	New
Soros Fund 30 Jun 2026	535,400	$37.8M	0.5%	New
Glenview Capital 30 Jun 2026	58,324	$4.1M	0.1%	Reduced
Bridgewater Associates 30 Jun 2026	26,750	$1.9M	0.0%	Added to

All the funds and what they reported ›

Companies like this one

Same SEC industry (biological products, (no diagnostic substances)) first, then the rest of health care.

AMGN Amgen Inc GILD Gilead Sciences, Inc.MRNA Moderna, Inc.RVMD Revolution Medicines, Inc.BIIB Biogen Inc.RGEN Repligen Corp KRYS Krystal Biotech, Inc.IBRX ImmunityBio, Inc.

Every figure, year by year

10 fiscal years · 30 measures

	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Size
Revenue	563.0M	643.0M	714.0M	738.7M	931.0M	1.1B	1.1B	1.2B	1.2B	1.2B
Revenue growth	—	+14.2%	+11.0%	+3.5%	+26.0%	+18.7%	+2.8%	+2.0%	+5.2%	-0.4%
Operating income	120.6M	136.2M	146.7M	157.4M	237.3M	296.6M	298.9M	206.7M	102.3M	251.9M
Net income	76.1M	126.2M	96.1M	229.3M	140.4M	272.1M	285.3M	168.1M	73.4M	181.9M
Margins
Gross margin	66.5%	67.2%	66.3%	65.4%	68.0%	68.4%	67.7%	66.4%	64.8%	65.8%
Operating margin	21.4%	21.2%	20.5%	21.3%	25.5%	26.8%	26.3%	17.8%	8.4%	20.7%
Net margin	13.5%	19.6%	13.5%	31.0%	15.1%	24.6%	25.1%	14.5%	6.0%	15.0%
Free cash flow margin	22.8%	23.2%	21.9%	20.8%	33.1%	25.4%	19.0%	20.4%	21.0%	21.7%
R&D ÷ revenue	9.5%	8.6%	8.7%	8.8%	7.6%	7.9%	8.1%	8.3%	8.2%	7.8%
SG&A ÷ revenue	35.6%	37.4%	37.0%	35.3%	34.9%	33.7%	33.3%	40.2%	48.3%	37.2%
Cash
Free cash flow	128.5M	149.4M	156.2M	153.5M	307.9M	280.4M	216.1M	236.1M	256.6M	263.2M
Stock-based pay	14.6M	28.2M	32.3M	32.4M	49.0M	42.2M	39.2M	38.0M	40.8M	41.4M
Free cash flow after stock pay	113.9M	121.2M	123.9M	121.1M	258.9M	238.2M	176.9M	198.1M	215.7M	221.9M
Free cash flow to the firm	126.8M	152.1M	153.8M	171.3M	236.8M	246.0M	258.3M	217.2M	167.3M	244.2M
Free cash flow ÷ net income	1.7×	1.2×	1.6×	0.7×	2.2×	1.0×	0.8×	1.4×	3.5×	1.4×
Capex ÷ revenue	2.7%	3.3%	3.6%	7.0%	4.8%	4.1%	3.4%	5.4%	2.5%	2.4%
Returns
Return on invested capital	—	—	10.7%	9.4%	14.2%	15.1%	—	—	—	—
Return on equity	8.0%	11.7%	8.2%	16.6%	9.0%	16.0%	14.5%	8.1%	3.8%	8.6%
Return on assets	4.9%	7.9%	5.1%	11.3%	6.2%	11.9%	10.8%	6.2%	2.9%	7.0%
Asset turnover	0.4×	0.4×	0.4×	0.4×	0.4×	0.5×	0.4×	0.4×	0.5×	0.5×
Economic profit	—	—	6.0M	-11.2M	63.3M	84.6M	—	—	—	—
Per share
Earnings per share	$0.51	$0.83	$0.62	$1.45	$0.87	$1.66	$1.76	$1.05	$0.46	$1.16
Free cash flow per share	$0.86	$0.98	$1.00	$0.97	$1.90	$1.71	$1.34	$1.47	$1.61	$1.68
Dividend per share	$0.32	$0.32	$0.31	$0.31	$0.31	$0.31	$0.31	$0.31	$0.32	$0.32
Payout ratio	62.2%	38.0%	50.3%	21.3%	35.3%	18.4%	17.6%	30.0%	68.7%	27.4%
Book value per share	$6.36	$7.17	$7.68	$8.98	$10.03	$10.86	$12.47	$13.08	$12.38	$13.51
Diluted shares	150.0M	152.2M	155.6M	157.6M	161.9M	164.1M	161.9M	160.8M	159.7M	157.0M
Balance sheet
Net debt	—	—	-88.4M	-134.1M	-186.6M	-160.1M	—	—	—	—
Net debt ÷ EBITDA	—	—	-0.4×	-0.6×	-0.6×	-0.4×	—	—	—	—
Interest coverage	16.4×	13.4×	6.8×	8.2×	17.0×	26.2×	26.7×	13.1×	12.0×	26.2×
Current ratio	2.6×	5.0×	4.0×	4.9×	3.4×	3.4×	4.8×	3.9×	3.5×	4.5×
Cash conversion cycle (days)	160	185	184	175	164	176	215	209	201	213
Scores
Piotroski F-score	—	7	3	5	6	8	4	4	5	7
Altman Z''	4.72	5.89	4.92	5.81	5.65	6.70	6.68	6.64	5.89	8.20
Beneish M	—	-2.47	-2.57	-2.52	-2.82	-2.38	-2.17	-2.70	-3.08	-2.60

Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.